We performed internal quality audits for a large pharmaceutical company. Our audits included manufacturing sites, distribution centers and two clinical trials. The audits results in several corrective actions that the company implemented internally. The FDA later performed onsite inspections of the manufacturing sites and 2 BIMO inspections. The FDA inspections resulted in no 483s. The site was able to implement corrective actions prior to inspection.